Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
PURPOSE: Ras/Raf/mitogen-activated protein-extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling is critical for tumor cell proliferation and survival. Selumetinib is a potent, selective, and orally available MEK1/2 inhibitor. In this study, we evaluated the therapeutic efficacy of...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797054074973061120 |
|---|---|
| author | Takahashi, O Komaki, R Smith, P Jürgensmeier, J Ryan, A Bekele, B Wistuba, I Jacoby, J Korshunova, M Biernacka, A Erez, B Hosho, K Herbst, R O'Reilly, MS |
| author_facet | Takahashi, O Komaki, R Smith, P Jürgensmeier, J Ryan, A Bekele, B Wistuba, I Jacoby, J Korshunova, M Biernacka, A Erez, B Hosho, K Herbst, R O'Reilly, MS |
| author_sort | Takahashi, O |
| collection | OXFORD |
| description | PURPOSE: Ras/Raf/mitogen-activated protein-extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling is critical for tumor cell proliferation and survival. Selumetinib is a potent, selective, and orally available MEK1/2 inhibitor. In this study, we evaluated the therapeutic efficacy of selumetinib alone or with cediranib, an orally available potent inhibitor of all three VEGF receptor (VEGFR) tyrosine kinases, in murine orthotopic non-small cell lung carcinoma (NSCLC) models. EXPERIMENTAL DESIGN: NCI-H441 or NCI-H460 KRAS-mutant human NSCLC cells were injected into the lungs of mice. Mice were randomly assigned to treatment with selumetinib, cediranib, paclitaxel, selumetinib plus cediranib, or control. When controls became moribund, all animals were sacrificed and assessed for lung tumor burden and locoregional metastasis. Lung tumors and adjacent normal tissues were subjected to immunohistochemical analyses. RESULTS: Selumetinib inhibited lung tumor growth and, particularly at higher dose, reduced locoregional metastasis, as did cediranib. Combining selumetinib and cediranib markedly enhanced their antitumor effects, with near complete suppression of metastasis. Immunohistochemistry of tumor tissues revealed that selumetinib alone or with cediranib reduced ERK phosphorylation, angiogenesis, and tumor cell proliferation and increased apoptosis. The antiangiogenic and apoptotic effects were substantially enhanced when the agents were combined. Selumetinib also inhibited lung tumor VEGF production and VEGFR signaling. CONCLUSIONS: In this study, we evaluated therapy directed against MEK combined with antiangiogenic therapy in distinct orthotopic NSCLC models. MEK inhibition resulted in potent antiangiogenic effects with decreased VEGF expression and signaling. Combining selumetinib with cediranib enhanced their antitumor and antiangiogenic effects. We conclude that combining selumetinib and cediranib represents a promising strategy for the treatment of NSCLC. |
| first_indexed | 2024-03-06T18:52:27Z |
| format | Journal article |
| id | oxford-uuid:10b68dd8-46bc-40b8-b9dc-dccc9ede10e8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:52:27Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:10b68dd8-46bc-40b8-b9dc-dccc9ede10e82022-03-26T09:57:53ZCombined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:10b68dd8-46bc-40b8-b9dc-dccc9ede10e8EnglishSymplectic Elements at Oxford2012Takahashi, OKomaki, RSmith, PJürgensmeier, JRyan, ABekele, BWistuba, IJacoby, JKorshunova, MBiernacka, AErez, BHosho, KHerbst, RO'Reilly, MSPURPOSE: Ras/Raf/mitogen-activated protein-extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling is critical for tumor cell proliferation and survival. Selumetinib is a potent, selective, and orally available MEK1/2 inhibitor. In this study, we evaluated the therapeutic efficacy of selumetinib alone or with cediranib, an orally available potent inhibitor of all three VEGF receptor (VEGFR) tyrosine kinases, in murine orthotopic non-small cell lung carcinoma (NSCLC) models. EXPERIMENTAL DESIGN: NCI-H441 or NCI-H460 KRAS-mutant human NSCLC cells were injected into the lungs of mice. Mice were randomly assigned to treatment with selumetinib, cediranib, paclitaxel, selumetinib plus cediranib, or control. When controls became moribund, all animals were sacrificed and assessed for lung tumor burden and locoregional metastasis. Lung tumors and adjacent normal tissues were subjected to immunohistochemical analyses. RESULTS: Selumetinib inhibited lung tumor growth and, particularly at higher dose, reduced locoregional metastasis, as did cediranib. Combining selumetinib and cediranib markedly enhanced their antitumor effects, with near complete suppression of metastasis. Immunohistochemistry of tumor tissues revealed that selumetinib alone or with cediranib reduced ERK phosphorylation, angiogenesis, and tumor cell proliferation and increased apoptosis. The antiangiogenic and apoptotic effects were substantially enhanced when the agents were combined. Selumetinib also inhibited lung tumor VEGF production and VEGFR signaling. CONCLUSIONS: In this study, we evaluated therapy directed against MEK combined with antiangiogenic therapy in distinct orthotopic NSCLC models. MEK inhibition resulted in potent antiangiogenic effects with decreased VEGF expression and signaling. Combining selumetinib with cediranib enhanced their antitumor and antiangiogenic effects. We conclude that combining selumetinib and cediranib represents a promising strategy for the treatment of NSCLC. |
| spellingShingle | Takahashi, O Komaki, R Smith, P Jürgensmeier, J Ryan, A Bekele, B Wistuba, I Jacoby, J Korshunova, M Biernacka, A Erez, B Hosho, K Herbst, R O'Reilly, MS Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. |
| title | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. |
| title_full | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. |
| title_fullStr | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. |
| title_full_unstemmed | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. |
| title_short | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. |
| title_sort | combined mek and vegfr inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis growth and metastasis |
| work_keys_str_mv | AT takahashio combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT komakir combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT smithp combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT jurgensmeierj combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT ryana combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT bekeleb combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT wistubai combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT jacobyj combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT korshunovam combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT biernackaa combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT erezb combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT hoshok combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT herbstr combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis AT oreillyms combinedmekandvegfrinhibitioninorthotopichumanlungcancermodelsresultsinenhancedinhibitionoftumorangiogenesisgrowthandmetastasis |